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Aims To asses whether clinically severe insulin
resistance and poor metabolic control in patients with
type II diabetes are associated with aberrant
expression or function of the p21ras pathway.
Methods We examined the expression and function
of the p21ras pathway in resting and activated PBMC
from 10 insulin treated patients with type II diabetes
characterized by high insulin requirements and poor
metabolic control (IR group) and 10 age and sex
matched well controlled patients treated by diet
alone or oral hypoglycemic medications (WC group).
Results Levels of p21ras and its regulatory
elements: p21rasGAP and hSOS1, were comparable
in the two groups. The induced activities of p21ras
and its associated down-stream regulatory enzyme
MAP-kinase following TPA stimulation were also
comparable in the IR andWC patients.
Conclusions Taken together, these data indicate that
clinically significant severe insulin resistance does
not modify the expression, regulation and activation
of p21ras pathway in PBMC of patients with type II
diabetes.
Keywords: Type II diabetes; Insulin resistance; PBMC; p21ras;
ras-GAP; hSOS; PBMC
Abbreviations: ECL, Enhanced Chemiluminescence; GAP,
GTPase Activating Protein; GlyHb, Glycated Hemoglobin;
GNRF, Guanine Nucleotide Releasing Factor; hSOS1,
human Son of Sevenless; MAP-kinase, Mitogen Activated
Protein kinase; PBMC, Peripheral Blood Mononuclear Cells;
PHA, Phytohaematoagglutinin; PKC, Protein Kinase C; TCR,
T cell Receptor; TK, Tyrosine Kinase; TPA, 12-0-tetrade-
canoylphorbol-13-acetate
INTRODUCTION
The p21ras protooncogenes are a heterologous
family of GTP/GDP-binding, growth promoting
proteins located downstream of receptor
associated TK’s in many cell types. The activity of
these proteins is regulated by their bound
GTP/GDP ratio and is directly proportional to
this ratio; GTP-p21ras and GDP-p21ras are the
active and the non-active states, respectively. The
relative amounts of GTP and GDP bound to
p21ras are regulated by two opposing factors.
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GNRF’s, such as SOS, enhance GTP binding to
p21ras by accelerating the dissociation of pre-
bound GDP. The 120 kDa p21rasGAP and other
GAP-like proteins enhance the relatively weak
intrinsic GTPase activity of non-transforming
p21ras proteins. [1,21 In lymphoid cells, stimulation
of membranal receptors such as the TCR or the
IL-2 receptors activates the TK’s or the PKC
dependent intracellular signaling pathways
which mediate p21ras-GAP inhibition and
increased hSOS activity resulting ultimately in
activatio L. p21ras -[3]
Insulin resistance plays a major role in the
pathogenesis and progression of Type II
Diabetes. Its cause is unknown in the vast
majority of patients and is commonly attributed
to post insulin receptor signaling defect. [41
Insulin receptor signaling is mediated in part via
the p21ras pathway.[5-7] Over-expression of a
p21ras like protein called "ras associated with
diabetes" (RAD) has been reported in muscle
tissue of patients with type II diabetes and
implicated as a cause of insulin resistance in
these patients. [8] However, genetic studies failed
to confirm a linkage between the rad locus and
familial predisposition to type II diabetes. [9]
Furthermore, we previously reported that the
induced activity, as well as expression of p21ras
and its regulatory factors were normal in PBMC
of insulin treated type II patients and
comparable to non-diabetic control patients.[1]
In this work, we examined for the first time the
function and expression of the p21ras pathway
in a subset of these patients characterized by
high insulin requirements and poor metabolic
control to further determine the role of p21ras
pathway in mediating the insulin resistance in
type II diabetes.
PATIENTS AND METHODS
Ten insulin treated type II diabetes patients with
severe insulin resistance and poor metabolic
control, mean age 58.8 __+ 11.3 years, range 46-68,
and 10WC patients treated with diet alone or oral
hypoglycemic medications, mean age 54.8+6.7
years, range 42-70, participated in the study.
Mean disease duration was 15 +__4 years and 8 +__ 6
years respectively. Clinical and demographic
parameters of these patients appear in Table I.
Classification of the patients was made according
to the National Diabetes Data Group guide-
lines. [11] None of the diabetic patients or controls
suffered at the time of his enrollment from any
other significant acute or chronic disease. Insulin
resistance was defined as daily insulin require-
ments >1 Unit/kg/day. None of the patients in
the IR group suffered from any endocrinopathies,
metabolic derangements or genetic syndromes
associated with clinical insulin resistance. Only
one patient from the insulin resistance group had
detectable but insignificant low levels of anti-
insulin antibodies. All participants signed an
informed consent and the hospital ethics com-
mittee approved the study. Twenty ml of blood
was drawn from an antecubital vein into
heparinized tubes from each patient. PBMC were
isolated by Ficol-Hypaque gradient centrifuga-
tion. Cells were either used immediately for the
p21ras/MAPK activity and proliferation assays,
or frozen and kept at -70C for the western blots.
Antibodies
Rabbit anti-GAP polyclonal antibody was
purchased from Santa Cruz Biotechnology (CA,
USA). Purified ascites containing Y13-259 anti
p21v-H-ras mAb was kindly donated by Dr. G. B.
Mills (Toronto General Hospital, Toronto, ON,
Canada). The rabbit anti hSOS1 polyclonal Ab
was purchased from UBI (Lake Placid NY, USA).
In Vitro Proliferation Assay
2 105 cells/well were cultured in RPMI medium
supplemented with 5% heat inactivated bovine
calf serum, glutamine 2mM, penicillin 100 U/ml,
200mg/dl glucose and streptomycin 100g/ml
(Biological Industries, Beit Haemek, Israel) in
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Group
TABLE Clinical and demographic parameters of the study patients and controls
Di"sease Insuiin MI’ ^Glycated
Number of AGE yrs duration yrs U/Kg/D kg/m **Hb%
patients (m/f) (mean+SD) (mean+SD) (mean+SD) (mean+SD) (mean+SD)
IR 10(6/4)
WC 10(6/4)
#P 0.008.
^P K 0.002.
**Normal range 6.8-8.8%.
58.8 11.3 15 __+ 3.9 1.43 +_ 0.5 30.8 4.9 12.3 +__ 1.4
54.8 __+ 6.7 8 +__ 5.9 30.6 +__ 6.9 8.2 0.6
0.2ml round-bottomed microtiter plates. Cells
were cultured for 3 days in 5% CO2 in air
humidified 37C incubator in the presence of
different concentrations of PHA (2.5-20g/ml).
Proliferative response to was assessed by 3H-
thymidine uptake (20h pulse) and calculated as
stimulation index (maximal proliferation in cpm
divided by the background non-stimulated value
of each patient).
Determination of p21ras Activity
Cells (1 107mL) were permeabilized by addition
of 0.4U/mL of streptolysin O (Gibco) and labeled
with 5Ci of o-[32P]GTP(5mCi; 3000 Ci/mmol,
Amersham), as described.[1] The CHELATE
program [12] was used to predict the concentration
of CaC12 and MgC12 required to give 100nM and
5mm free Ca2+ and free Mg2+, respectively, at
pH 7.2 and 37C. After stimulation with TPA
(10nM) (Sigma Immunochemicals) for 20 rain,
cells were lysed in ice-cold 50mM Hepes buffer,
pH 7.4, containing 1% NP-40, lmM EGTA,
150mM NaC1, 5mM MgC12, 1raM PMSF,
10mg/ml leupeptin, 10mg/mL aprotinin,
10mg/ml soybean trypsin inhibitor, 0.5%
deoxycholate and 0.05% SDS. Lysates were
precleared for 5 min at 4C with goat anti-rat IgG
coupled to agarose (Sigma Immunochemicals).
Immunoprecipitations (45min at 4C) were per-
formed in duplicate using 5g/ml of either Y13-
259 anti p21v-H-ras mAb or normal rat IgG
(Jackson Immunoresearch Laboratories, West
Grove, PA), followed by goat anti-rat IgG
coupled to agarose. After washing (lm18),
nucleotides were eluted by incubation for 20min
at 68C, and separated on polyethylene-imine-
cellulose, thin layer, chromatography plates
developed in 1M KH2PO4, pH 3.4. Plates were
autoradiographed and determination of ras-
bound GTP/GDP was evaluated by photoden-
sitometry (Computing densitometer, molecular
dynamics, Model 300A; Eugene OR).
Western Blots
2 X 107 Cells were lysed in lysis buffer and boiled
for 2min in SDS sample buffer. Proteins
(50g/lane) were separated by SDS-PAGE,
transferred to nitrocellulose membrane and
immunoblotted with either Y13-259 anti-p21v
H-ras mAb (4g/ml), rabbit anti-GAP polyclonal
antibody (lg/ml) or the rabbit anti-hSOS1
polyclonal Ab (4g/ml). Normal rat IgG or
normal rabbit preimmune serum were used as
control for the determination of p21ras,
120rasGAP and hSOS1, respectively. Anti-rat and
anti-rabbit HRP mAb’s were used successively
for blotting of p21ras and 120rasGAP,
respectively. Membranes were developed with
ECL and autoradiographed. Protein expression
was determined by photodensitometery
(Computing densitometer, Molecular dynamics,
Model 300A; Eugene OR).
MAP-kinase Activity Assay
Determination of MAP-kinase activity was
[13] performed as previously described. Briefly,
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following stimulation cells (107/treatment) were
frozen at -70C, thawed and homogenized in
501xl of 50mM /-glycerol phosphate buffer
(pH 7.3) containing 1.5mM EGTA, lmM EDTA,
lmM dithiotreitol, 0.1mM sodium vanadate,
10g/ml leupeptin, 10txg/mL aprotinin and
10g/ml pepstatin A. The homogenates were
centrifuged at 15,000g for 20min and the
supernatants (cytosolic extracts) were sup-
plemented with five fold concentrated sample
buffer (300mm Tris-HCL, pH 6.8, 10% [w/v] SDS,
25% [v/v] glycerol and 0.025% [w/v] pyronine y).
A gel shift assay was performed by applying
the cytosolic extract on SDS-PAGE using poly-
acrylamide. (10%w/v) and bisacrylamide
(0.1%w/v) to obtain optimal separation of the
phosphorylated and non-phosphorylated forms of
MAP-kinase. The proteins were transferred onto
nitrocellulose membrane and reacted with rabbit
polyclonal antibodies to MAP-kinase (1:2000
dilution). he enzyme was detected with ECL kit
according to manufacturer’s instructions.
(data not shown). These data indicate that severe
insulin resistance does not modify p21ras
expression in PBMC of patients with type II
diabetes.
Expression of p21ras Regulatory Elements
is Normal in Insulin Resistant Patients
To further examine the regulation of p21ras
pathway in insulin resistant patients we deter-
mined the levels of the p21ras inhibitory element
p120rasGAP and the stimulatory factor hSOS1 in
these patients. Expression of p21ras-GAP and
hSOS1 were comparable in the two groups:
2289 + 979 and 1833+ 300 and 625 + 183 and
731 +226 for insulin resistant and well-controlled
A
hSOSl
WC IR
Statistical Analysis
Statistical analysis was carried out by Student’s
t-test for comparisons of means. Differences
between groups were considered statistically sig-
nificant at p< 0.05.
RESULTS
Normal p21ras Expression in IR Patients
To examine the p21ras pathway, we initially
determined the levels of p21ras in our insulin
resistant and well-controlled patients. Expression
of p21ras was comparable in the two groups:
2904 +830 and 3012 ___256 in insulin resistant and
well controlled patients, respectively (Fig. 1). No
correlation was found between p21ras expression
and any of the clinical or demographic param-
eters of these patients including metabolic control,
disease duration or daily insulin requirements
pl20rasGAP
p21ras
B 4000
3000
2000
ooo
0
p21ras rasGAP hSOS
FIGURE Expression of p21ras, p120rasGAP and hSOS1
proteins is comparable in well-controlled (WC) and insulin
resistant (IR) type II diabetic patients.
(A) Representative western blots of p21ras, p120rasGAP
and hSOS1 from PBMC of well-controlled (WC) and insulin
resistant (IR) diabetic patients.
(B) Expression of p21ras, p120 rasGAP and hSOS1 in
PBMC lysates ofWC (empty bars) and IR (black bars). Protein
concentrations were determined by photodensitometry as
indicated. Values represent SEfor each group.
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patients, respectively (Fig. 1). These data indicate
that the regulation of p21ras pathway in PBMC of
type II patients with severe insulin resistant is
normally maintained.
P21ras Pathway Activation in Insulin
Resistant Patients
Activation of p21ras pathway may be decreased
in the presence of normal expression of p21ras
and its regulatory elements.[1,14,15] Therefore, we
determined the stimulated p21ras guanine
nucleotide binding in the three most insulin
B
GDP
GTP
14
WC
CONT TPA
WC IR
IR
CONT TPA
FIGURE 2 p21ras activation in well-controlled (WC) and
insulin resistant (IR) type II diabetic patients.
(A) Representative thin layer chromatogram of p21ras-
bound nucleotides eluted from PBMC of well-controlled
and insulin-resistant patients. Cells were either non-
stimulated (CONT) or stimulated with TPA 10ng/ml for
10 min (TPA).
(B) Activation of p21ras in PBMC ofWC (empty bars) and
IR (black bars) patients, p21ras activation (AGTP) was
calculated as the percent difference between the ratio of
GTP/GDP+GTP of stimulated and non-stimulated cells.
Each bar represents mean SE of each group.
resistant patients (mean daily insulin require-
ments 1.6U/Kg/D+0.5, mean GlyHb 13.1% +
1.2) as compared to WC patients (mean GlyHb
7.9% +0.4). Figure 2 shows that TPA stimulated
increase in p21ras activity was comparable in
insulin resistant and well-controlled patients:
6.45 +3.5% and 5.7+ 7%, respectively. To fu.rther
analyze this pathway we determined the stim-
ulated activity of p21ras down-stream associated
regulatory enzyme MAP-kinase. Exposure to TPA
resulted in a similar electrophoretic shift in the
phosphorylated 44 kDA form of MAP-kinase:
30.9% + 5.7 and 28.7% __+ 3.5 of total MAP-kinase
for IR and WC patients, respectively (Fig. 3). No
correlation was found between the degree of
p21ras activation and various clinical parameters
of these patients including: age, disease duration,
insulin requirements in Units/kg/day and
WC IR
[control llc0=’oZ ’e"l
B 4O
30
"
20
: 10
O
WC IR
FIGURE 3 Activation of MAP kinase by TPA in PBMC of
type II diabetic patients.
Cells from well-controlled (WC) and insulin resistant (IR)
patients were exposed to 10nM of TPA for 10min before
MAP kinase analysis was performed as described in
methods.
(A) Representative immunoblot of cytosolic extract
developed with anti MAP kinase antibody. The arrow
indicates the electrophoretic shift of MAP kinase induced by
TPA.
(B) Densitometric analysis of MAP kinase activation in
WC (empty bars) and IR (black bars) patients. Data (mean
SE of each group) shows the phosphorylated form of MAP
kinase expressed as percent of total MAP kinase.
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WC IR
FIGURE 4 Proliferative response of PBMC from well-con-
trolled (WC) and insulin resistant (IR) patients.
PBMC were isolated from WC (empty bars) and IR (black
bars) patients as described. Maximal proliferative response to
PHA (2.5-20tg/ml) was assessed after three days by 3H-
thymidine uptake (20 h pulse). Values represent mean _+ SE of
each group and are expressed in SI units calculated as the
maximal proliferation in cpm divided by the background non-
stimulated value of each patient.
GlyHb levels. Taken together, these data indicate
that the basal and stimulated activities of p21ras
pathway is normal in PBMC of type II patients
characterized by severe insulin resistance.
Normal Proliferative Response of PBMC
from Insulin Resistant Patients
We previously reported a normal p21ras pathway
expression in the presence of defective lympho-
cyte activation and proliferation. [14] Therefore, we
determined the mitogen mediated in vitro
proliferation of our insulin resistant and well-
controlled patients. The mean proliferative re-
sponse to PHA was comparable in insulin
resistant and well-controlled patients: SI of
16.4 + 8.6 and 14.5_ 7.8, respectively (Fig. 4).
Exposure to insulin alone (1-10nm) did not
result in a significant proliferative response in
both groups (data not shown).
Thus, severe chronic hyperglycemia and high
insulin requirements do not decrease the lympho-
cyte proliferative response of type II diabetic
patients.
DISCUSSION
Our data demonstrate that the expression of
p21ras and its regulatory factors in lymphocytes
of poorly controlled type II diabetic patients with
high insulin requirements are comparable to well
controlled patients. No correlation was found
between the expression of the p21ras pathway
constituents in these patients and any of their
clinical parameters including disease duration,
glycated Hb levels and BMI or daily insulin
requirements. This suggests that the p21ras
pathway is not affected by the long standing
severe insulin resistance and the resulting poor
metabolic control of patients with type II
diabetes. Furthermore, it does not support a role
for this pathway in mediating the insulin
resistance of these patients. These findings differ
from the findings of Reynet et al who have
reported increased expression of p21ras like
protein namely rad in muscle tissue of type II
diabetic patients. [81 This discrepancy could result
from the methodological differences between
the two studies i.e., protein levels vs. mRNA
determination or the minor but significant
sequence differences between p21ras and rad. It
could also result from the different tissues
examined i.e., muscle Vs. lymphocytes. If this is
the.case it may indicate that p21ras or p21ras like
protein over expression in type II diabetic
patients is not an inherent generalized finding in
insulin responsive tissues of these patients but is
rather tissue specific.
We previously demonstrated that reduced
activation of the p21ras pathway is detectable in
the presence of normal expression of p21ras and
its regulatory factors.[1,14,151 In addition, a
variety of signaling defects has been reported in
PBMC from type II patients [16-18I and hyper-
glycemia has been implicated as a reversible
cause of aberrant T cell activation in diabetic
patients. [19] This raised the question whether
p21ras signaling rather than expression is
affected by long standing hyperglycemia. Our
data demonstrate that TPA mediated activation
of p21ras and activation of its downstream
regulatory enzyme MAP kinase is intact in the
subset of patients with the most severe insulin
resistance and comparable to well-controlled
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patients. This suggests that the functional
integrity of the p21ras/MAP kinase pathway is
normally maintained in insulin resistant type II
patients. This notion is in agreement with the
recent demonstration of a normal expression
and insulin mediated MAP kinase phos-
phorylation in isolated skeletal muscle from
moderately controlled type II diabetic
patients.[2] However, it should be pointed out
that we examined only the downstream part of
the p21ras pathway. Thus, it remains possible
that severe insulin resistance and poor metabolic
control affect the early membrane receptor
mediated activation of p21ras pathway rather
than disrupt its late signaling events. This
intriguing possibility is consistent with the
reported down-regulating effect of glucose
toxicity on early insulin receptor signaling
cascade [21,221 and by the recent demonstration
that ras transformed brown adipocytes devel-
oped insulin resistance due to a signaling defect
up-stream of ras, without decreasing the activity
of p21ras down-stream elements. [23] It is also
supported by our previous demonstration in
type I patients and pre-diabetic animals of a
restricted defect in the activation of p21ras
located up-stream of PKC p21ras complex and
the cell membrane.[1,14A5] It should also be
pointed out that we did not provide here data
regarding the effect of insulin itself on
p21ra/MAP kinase pathway activity in our
patients inasmuch as exposure to insulin in
physiological concentrations in vitro did not
result in any detectable increase in their GTP-
p21ras (data not-shown). This is consistent with
the reported effects of other hormones such as
hGH which act via the p21ras pathway. The
small but detectable effect on the p21ras
pathway of the latter is achieved only when its
concentration is at least one order of magnitude
higher than that necessary for mitogenesis. [131
Furthermore, others have reported that an
overexpression of the insulin receptor is
necessary to examine the effect of insulin on
p21ras pathway activity in vitro. [71 Thus, our
current experiments do not allow us to decide
whether insulin-mediated signaling via the
p21ras/MAP kinase pathway remains unaltered
in our insulin resistant patients.
In conclusion, our data provide evidence for a
normal expression and activation of p21ras
pathway in PBMC of poorly controlled type II
diabetic patients with clinically significant insulin
resistance. Further studies with a larger number
of patients and examination of a wide range of
insulin responsive tissues are necessary to
determine the role of the p21ras pathway in
mediating insulin resistance in these patients.
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